Uncovering Outcome Disparities of β(2) Adrenergic Agonists in Blacks: A Systematic Review.
Uncovering Outcome Disparities of β(2) Adrenergic Agonists in Blacks: A Systematic Review.
复制标题
揭示β（2）黑人肾上腺素能激动剂的结果差异：系统评价。
DOI：
10.1016/j.jnma.2020.07.001
复制
发表时间：
2021-03
影响因子：
3.3
通讯作者：
Wilkins CH
中科院分区：
文献类型：
--
作者：
Jerome RN;Pulley JM;Sathe NA;Krishnaswami S;Dickerson AB;Worley KJ;Lima MF;Wilkins CH
黑人对治疗的生物学反应差异导致的结果差异可能导致哮喘发病率和死亡率的持续种族差异。本综述评估了黑人与其他组相比β2激动剂治疗结果的系统变化。我们对报告黑人对β2激动剂的不同反应的研究进行了系统回顾，包括确定药物遗传变异的研究。在3158篇论文中，20篇比较了β2激动剂在黑人中的安全性或有效性，并与其他亚组进行了比较。六篇评估短效β2激动剂（SABA）疗效的论文发现，与其他组相比，黑人的效果相似或有所改善，而一项小型研究发现黑人对SABA治疗的反应降低。四篇关于长效β2激动剂（LABA）的安全性和有效性的报告表明，黑人的结果相似，而四篇报告发现，与其他组相比，黑人的安全性降低。四篇论文评估了黑人的基因组变异和相对治疗反应，其中两篇发现ADRB2中p.a g16gly变异对β2激动剂反应有显著影响，一篇发现基因-基因IL6/IL6R相互作用对沙丁胺醇反应有显著影响。有证据表明，与其他群体相比，黑人β2激动剂的结果可能存在差异。然而，这方面的文献仍然很少，而且不足以得出实质性的结论。对于β2激动剂在黑人中的安全性和有效性进行充分有力的研究，包括药物基因组学修饰剂的反应，有明显的机会。
Outcome differences driven by variation in Blacks’ biologic response to treatment may contribute to persistent racial disparities in asthma morbidity and mortality. This review assessed systematic variation in β2 agonist treatment outcomes among Blacks compared to other groups. We conducted a systematic review of studies reporting differential response to β2 agonists among Blacks, including studies identifying pharmacogenetic variants. Of 3158 papers, 20 compared safety or efficacy of β2 agonists among Blacks as compared with other subgroups. Six papers evaluating efficacy of short-acting β2 agonists (SABA) found similar or improved results among Blacks compared with other groups, while one small study found reduced response to SABA therapy among Blacks. Reports of safety and efficacy of long-acting β2 agonists (LABA) indicated similar results among Blacks in four papers, while four reports found reduced safety among Blacks, as compared with other groups. Four papers assessed genomic variation and relative treatment response in Blacks, with two finding significant effects of the p.Arg16Gly variant in ADRB2 on β2 agonist response and one finding significant gene-gene IL6/IL6R interaction effects on albuterol response. Evidence suggests the potential for differences in β2 agonist outcomes among Blacks compared with other groups. This literature, however, remains small and significantly underpowered for substantive conclusions. There are notable opportunities for adequately-powered investigations exploring safety and efficacy of β2 agonists among Blacks, including pharmacogenomic modifiers of response.
登录
查看更多内容
影响因子：
7.4
作者：
Noponen-Hietala, N;Virtanen, L;Ala-Kokko, L
通讯作者：
Ala-Kokko, L
影响因子：
1.9
作者：
Naqvi, Mariam;Thyne, Shannon;González, Esteban
通讯作者：
González, Esteban
影响因子：
2.6
作者：
Corvol, Harriet;De Giacomo, Anthony;Burchard, Esteban Gonzalez
通讯作者：
Burchard, Esteban Gonzalez
影响因子：
15.9
作者：
Fishman, D;Faulds, G;Woo, P
通讯作者：
Woo, P
影响因子：
9.6
作者：
Nelson, HS;Weiss, ST;Dorinsky, PM
通讯作者：
Dorinsky, PM